Table 5. Studies describing serologic response to influenza vaccination in patients with solid tumors.

Author and year of publication	Setting	Patient population	N of patients	Influenza season	Time point titres drawn post-vaccination	Seroconversion	Seroprotection	Timing in relation to chemotherapy
Ortbals 19774	St.Louis, MO, USA	Lymphoreticular neoplasms Solid tumors Controls	21 21 96	Not mentioned	Baseline, 2 weeks and 4 weeks	67% to A/NJ/76 76% to A/NJ/76 90% to A/NJ/76	Not assessed	Randomized to vaccine on same day as chemotherapy, or a week before
Stiver 197715	Canada	Lymphoreticular Solid (13 had breast cancer) Controls	19 16 27	1975	2-8 weeks	31.8% for H3N236.4% for B 74% for H3N293% for B	Not assessed	Not assessed
Ganz 197816	Los Angeles, CA, USA	Solid tumors and lymphomas Controls	17 15	1976	2 weeks and 4 weeks	41-47% for each strain 67% for each strain	Not assessed	Not assessed
Shildt 197911	Fort Sam Houston, TX, USA	Solid tumors and lymphoma, including 22 patients with solid tumors receiving chemotherapy			3 and 9 weeks	41-59% for each strain at 3 weeks	32-86% for each strain at 3 weeks	Not assessed, included patients on treatment (chemotherapy or radiation) versus those off
Anderson 199912	UK	Lung cancer, only 14 had received chemotherapy in the preceding month	59	1996	4-6 weeks	Not assessed	83%	Not assessed
Brydak 200013	Poland	Breast cancer Controls	9 19	1998-1999	Baseline and 1 month	88.8% to one or more strain 100% to one or more strain	44.4% – 88.9% for each strain 63.2% - 94.7% for each strain	Not assessed
Kim 201314	Korea	Colorectal cancer	40	2009-2011	1-2 months	26.3% - 52.6% for each strain	42.1%-94.7% for each strain	Not assessed
Loulergue 201117	France	Breast cancer prostate cancer	18 12	2008-2009	21 days	16-28% for each strain	Not assessed	All on day 1 of chemotherapy